U.S. Markets closed

Innovus Pharmaceuticals, Inc. (INNV)

OTC Markets - OTC Markets Delayed Price. Currency in USD
Add to watchlist
0.117+0.009 (+8.837%)
At close: 3:57PM EDT
People also watch

Innovus Pharmaceuticals, Inc.

9171 Towne Centre Drive
Suite 440
San Diego, CA 92122
United States

IndustryDrug Manufacturers - Major
Full Time Employees5

Key Executives

Dr. Bassam B. Damaj Ph.D.Chief Exec. Officer, Pres & Director532.4kN/A49
Mr. Rauly Gutierrez CPAPrincipal Financial and Accounting OfficerN/AN/AN/A
Mr. Randy J. Berholtz Esq., J.D., MBAExec. VP - Corp. Devel. & Gen. CounselN/AN/A55
Mr. Robert C. VerfurthVP of Sales & MarketingN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Innovus Pharmaceuticals, Inc., a pharmaceutical company, engages in the commercialization, licensing, and development of non-prescription medicine and consumer care products in the United States. Its products include Zestra, a proprietary blend of essential oils to enhance desire, arousal, and satisfaction in women; EjectDelay, an over-the-counter monograph-compliant benzocaine gel for premature ejaculation; Sensum+, a non-medicated cream that enhances penile sensitivity; Zestra Glide, a water-based longer lasting lubricant; Vesele, a proprietary oral supplement of Arginine sexual and cognitive functions; and Androferti, a natural supplement to support overall male reproductive health and sperm quality. The company also offers Beyond Human testosterone booster, Ketones, krill oil, Omega 3 fish oil, Vision Formula, blood sugar, colon cleanse, green coffee extract, and growth agent; RecalMax for brain health; and UriVarx, a proprietary supplement for overactive bladder and urinary incontinence. The company’s pipeline products include FlutiCare, an over the counter drug for Rhinitis; Urocis for urinary tract infection; Xyralid, a lidocaine based cream for the relief of pain and symptoms caused by hemorrhoids; AllerVarx, a patented formulation produced in bilayer tablets; and AndroVit, a proprietary supplement to support overall prostate and male sexual health. The company markets and sells its products through commercial partners to primary care physicians, urologists, gynecologists, and therapists, as well as to other healthcare providers; and directly to consumers through online channels, retailers, and wholesalers. Innovus Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

Corporate Governance

Innovus Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.